Atezolizumab is a type of medication known as an immunotherapy. It works by helping your immune system fight cancer cells. Specifically, it blocks a protein called PD-L1, which is found on some cancer cells. By blocking this protein, atezolizumab helps your immune system recognize and attack the cancer cells more effectively. In this trial, atezolizumab is being tested to see if it can improve survival in elderly patients with advanced non-small-cell lung cancer when used alongside other cancer treatments.

Carboplatin is a chemotherapy drug used to treat various types of cancer, including lung cancer. It works by damaging the DNA of cancer cells, which prevents them from growing and dividing. This helps to slow down or stop the spread of cancer in the body. In this trial, carboplatin is used in combination with other treatments to see if it can help improve outcomes for patients with advanced non-small-cell lung cancer.

Paclitaxel is another chemotherapy medication that is used to treat different kinds of cancer, such as lung cancer. It works by interfering with the normal function of microtubules during cell division, which stops cancer cells from dividing and growing. This can help to control the spread of cancer. In this study, paclitaxel is given alongside other treatments to evaluate its effectiveness in improving the survival of elderly patients with advanced non-small-cell lung cancer.

Non-Small Cell Lung Cancer – Non-Small Cell Lung Cancer (NSCLC) is a type of lung cancer that includes several subtypes, such as adenocarcinoma, squamous cell carcinoma, and large cell carcinoma. It typically begins in the tissues of the lungs and is characterized by the uncontrolled growth of abnormal cells. As the disease progresses, these cancerous cells can form tumors and may spread to other parts of the body, a process known as metastasis. NSCLC often grows and spreads more slowly than small cell lung cancer, which is another major type of lung cancer. Symptoms may include persistent cough, chest pain, and difficulty breathing, which can worsen as the disease advances. The progression of NSCLC can vary significantly among individuals, depending on factors such as the specific subtype and stage at diagnosis.